Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
REP 9AC (REP 2055) is a nucleic acid polymer (NAP) with entry and post-entry antiviral
activity against duck hepatitis B virus (DHBV) infection. REP 2055 has been shown to have
potent therapeutic effect against established DHBV infection in vivo
REP 2055 was additionally shown to have significant antiviral effects in patients with
chronic HBV infection in the previous REP 101 study. REP 2139 is a version of REP 2055
designed for improved administration tolerability and stability.
The safety and antiviral activity REP 2139, first in monotherapy and then in combination with
immunotherapy in patients with chronic HBV infection will be assessed in the REP 102
protocol.